CA2393292A1 - Elements de liaison specifiques du cerveau - Google Patents

Elements de liaison specifiques du cerveau Download PDF

Info

Publication number
CA2393292A1
CA2393292A1 CA002393292A CA2393292A CA2393292A1 CA 2393292 A1 CA2393292 A1 CA 2393292A1 CA 002393292 A CA002393292 A CA 002393292A CA 2393292 A CA2393292 A CA 2393292A CA 2393292 A1 CA2393292 A1 CA 2393292A1
Authority
CA
Canada
Prior art keywords
seq
specific binding
antibody
binding member
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002393292A
Other languages
English (en)
Inventor
Carl Webster
Jane Osbourn
George Ward
Karen Miller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2393292A1 publication Critical patent/CA2393292A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne des éléments de liaisons spécifiques dirigés vers le cerveau comprenant des éléments de liaisons spécifiques capables de passer la barrière hémato-encéphalique, ou qui sont dirigés vers des zones à affection cérébrale de caractère inflammatoire ou de rupture de la barrière hémato-encéphalique. L'invention concerne aussi des listes et des mélanges d'anticorps, des molécules d'anticorps individuel et des domaines VH et VL, ainsi que des procédés d'obtention d'éléments de liaisons spécifiques par sélection, c'est à dire par l'utilisation de bibliothèques présentées sur la surface du bactériophage filamenteux.
CA002393292A 1999-12-13 2000-11-27 Elements de liaison specifiques du cerveau Abandoned CA2393292A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17059999P 1999-12-13 1999-12-13
US60/170,599 1999-12-13
PCT/GB2000/004501 WO2001044300A2 (fr) 1999-12-13 2000-11-27 Elements de liaison specifiques du cerveau

Publications (1)

Publication Number Publication Date
CA2393292A1 true CA2393292A1 (fr) 2001-06-21

Family

ID=22620533

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002393292A Abandoned CA2393292A1 (fr) 1999-12-13 2000-11-27 Elements de liaison specifiques du cerveau

Country Status (5)

Country Link
EP (1) EP1242458A2 (fr)
JP (1) JP2003516745A (fr)
AU (1) AU770115B2 (fr)
CA (1) CA2393292A1 (fr)
WO (1) WO2001044300A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2732276T3 (es) 2001-08-23 2019-11-21 Rsr Ltd Regiones del epítopo de un receptor de tirotropina (TSH), usos del mismo y anticuerpos para el mismo
GB0414886D0 (en) * 2004-07-02 2004-08-04 Neutec Pharma Plc Treatment of bacterial infections
BRPI0606933B8 (pt) * 2005-01-24 2021-05-25 Cambridge Antibody Tech Limited membro de ligação específico isolado para fator de crescimento de nervos, molécula de anticorpo isolado, composição e uso de um membro de ligação específico
CN110251668A (zh) 2010-11-30 2019-09-20 霍夫曼-拉罗奇有限公司 低亲和力血脑屏障受体抗体及其用途
ES2924282T3 (es) * 2014-12-19 2022-10-05 Medimmune Ltd Moléculas de transporte a través de la barrera hematoencefálica y usos de las mismas

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5527527A (en) * 1989-09-07 1996-06-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
DE69637395T2 (de) * 1995-09-11 2008-12-18 La Jolla Cancer Research Foundation, La Jolla Moleküle, die sich in ausgewählten Organen oder Geweben in-vivo einfinden
EP0876615A1 (fr) * 1995-11-10 1998-11-11 Elan Corporation Plc Peptides accroissant le transport dans les tissus et procedes d'identification et d'utilisation correspondants
AU8269898A (en) * 1997-06-27 1999-01-19 Regents Of The University Of California, The Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor

Also Published As

Publication number Publication date
JP2003516745A (ja) 2003-05-20
WO2001044300A3 (fr) 2002-06-13
AU770115B2 (en) 2004-02-12
EP1242458A2 (fr) 2002-09-25
AU1713901A (en) 2001-06-25
WO2001044300A2 (fr) 2001-06-21

Similar Documents

Publication Publication Date Title
DE60317677T2 (de) Ox40 (=cd134) rezeptor agonisten und therapeutische verwendung
DE60012500T2 (de) Antikörper und antikörperfragmente mit spezifität für tgfbeta1
JP5127085B2 (ja) テネイシンｃに対する抗体
US9701746B2 (en) Methods of treating neuropathic pain with specific binding members for NGF
DE69737683T2 (de) Antikörper gegen die ed-b domäne von fibronektin, ihre herstellung und verwendungen
DE69607191T2 (de) Spezifische bindungspartner für menschlichen transformierenden wachstumsfaktor und verfahren
JP4773540B2 (ja) ヒト癌胎児性抗原に対する特異的結合メンバー；材料および方法
DE69927268T2 (de) Spezifische antikörper enthaltende bindungsproteine die das nekrotische tumorzentrum binden und deren verwendung
CZ301495A3 (en) Anti-epidermal growth factor and receptor one-chain antibody fragment thereof, process of its preparation and pharmaceutical composition containing thereof
CN106349389A (zh) 肿瘤特异性抗egfr抗体及其应用
KR101205655B1 (ko) 시냅토피신에 대한 특이적 결합 멤버
AU770115B2 (en) Brain specific binding members
Dong et al. Single chain Fv antibodies against neural cell adhesion molecule L1 trigger L1 functions in cultured neurons
CN114805581B (zh) 靶向il13ra2的抗体、嵌合抗原受体及其用途
MXPA00010434A (en) Methods of selecting internalizing antibodies

Legal Events

Date Code Title Description
FZDE Dead